Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31521747 | 0.75 | CYP17A1 (0.39) | CYP17A1MDM2PIK3CAEGFRPIK3CD | |
| SCHEMBL30816580 | 0.73 | CYP17A1 (0.39) | CYP17A1PIK3CAEGFRPIK3CDPIK3CB | |
| SCHEMBL3522137 | 0.66 | TDP1 (0.34) | — | |
| SCHEMBL29559729 | 0.66 | ERN1 (0.41) | CYP17A1EGFR | |
| SCHEMBL3521853 | 0.66 | ERN1 (0.41) | CYP17A1EGFR | |
| SCHEMBL30816561 | 0.65 | ALDH1A1 (0.44) | CYP17A1 | |
| SCHEMBL31521754 | 0.64 | GAA (0.42) | CYP17A1 | |
| SCHEMBL30816598 | 0.64 | NNMT (0.45) | CYP17A1 | |
| SCHEMBL31521740 | 0.64 | MAPK1 (0.42) | CYP17A1 | |
| SCHEMBL9761039 | 0.64 | MAPT (0.34) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | USP1, USP28, USP2 | CYP17A1 1682/4885MDM2 64/4885PIK3CA 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.